NASDAQ · APRE
Healthcare · Biotechnology
$0.64
Down-$0.05 (-7.14%)
Updated Oct 7, 2026, 6:26 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · APRE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
APRE closed at $0.64 after 21 trading sessions, down 23.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.68 | $0.68 | $0.6343 | $0.6355 | 199.17K |
| Oct 5, 2026 | $0.686 | $0.695 | $0.64 | $0.6756 | 296.49K |
| Oct 2, 2026 | $0.716 | $0.7362 | $0.685 | $0.695 | 862.3K |
| Oct 1, 2026 | $0.7635 | $0.7815 | $0.675 | $0.7235 | 779.69K |
| Sep 30, 2026 | $0.78 | $0.82 | $0.7405 | $0.75 | 582.21K |
| Sep 29, 2026 | $0.7579 | $0.82 | $0.75 | $0.7696 | 591.62K |
| Sep 28, 2026 | $0.76 | $0.7711 | $0.7402 | $0.7518 | 69.81K |
| Sep 25, 2026 | $0.78 | $0.7803 | $0.7414 | $0.7608 | 53.34K |
| Sep 24, 2026 | $0.80 | $0.80 | $0.7651 | $0.7797 | 52.25K |
| Sep 23, 2026 | $0.7424 | $0.81 | $0.7424 | $0.78 | 282.12K |
| Sep 22, 2026 | $0.76 | $0.76 | $0.7001 | $0.7324 | 189.65K |
| Sep 21, 2026 | $0.7599 | $0.7599 | $0.73 | $0.737 | 96.75K |
| Sep 18, 2026 | $0.78 | $0.78 | $0.74 | $0.7599 | 79.99K |
| Sep 17, 2026 | $0.75 | $0.772 | $0.73 | $0.75 | 117.51K |
| Sep 16, 2026 | $0.729 | $0.757 | $0.7111 | $0.7305 | 186K |
| Sep 15, 2026 | $0.82 | $0.82 | $0.7333 | $0.7488 | 184.18K |
| Sep 14, 2026 | $0.771 | $0.8427 | $0.76 | $0.7814 | 120.27K |
| Sep 11, 2026 | $0.7957 | $0.8199 | $0.7651 | $0.774 | 127.72K |
| Sep 10, 2026 | $0.7805 | $0.8101 | $0.7805 | $0.7892 | 61.33K |
| Sep 9, 2026 | $0.85 | $0.871 | $0.7832 | $0.7914 | 135.46K |
| Sep 8, 2026 | $0.8403 | $0.88 | $0.7788 | $0.835 | 323.72K |
The latest Smart Investors Daily articles mentioning APRE.
Company
Market Activity
Research & News
APRE research
Company profile and research snapshot.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Outperform | — |
| May 14, 2026 | Wedbush | Outperform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Mar 31, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with
Benzinga · Aug 27, 2026
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock increased by
Benzinga · Jul 30, 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Benzinga · Mar 3, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APRE.
